Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Nucleic Acids, Nucleotides, and Nucleosides
Clear Filters

Search Clinical Trials

24 Results
Not Yet Recruiting
Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
Once participants' eligibility has been confirmed, and participants have been registered in the study, the participants will receive immunotherapy treatment with Atezolizumab, followed by administration of CAPEOX chemotherapy for a …
Baylor Role: Lead Sponsor
Not Yet Recruiting
UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children
Dolutegravir (DTG), Emtricitabine (FTC) and Tenofovir alafenamide (TAF) are anti-HIV medicines. DTG works very well, can be taken once-daily and has few side effects. In international treatment guidelines, DTG is …
Baylor Role: Collaborator
Withdrawn
Azacytidine During Anti-tuberculosis Therapy
All study participants will have drug-sensitive TB and successfully complete 2 months of standard intensive phase 4-drug RHZE (rifampin, isoniazid, pyrazinamide, ethambutol). By definition, to have uncomplicated TB, participants will …
Recruiting
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
This study will include 370 children and young people aged 2 to less than 15 years old who are living with HIV and are being treated with anti-HIV medicines for …
Baylor Role: Collaborator
Withdrawn
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
A maximum of 42 subjects will participate in the treatment part of this study. The investigators will collect up to 180 mL of the participants blood. The investigators will use …
Baylor Role: Lead Sponsor
Completed
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
A maximum of 30 subjects will participate in the treatment part of this study. Up to 180ml of blood is collected from patients to grow the T cells. The T …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
Standard cytotoxic chemotherapy is based on the Medical Research Council (MRC) backbone of cytarabine, and daunorubicin. This combination of chemotherapy is highly myelosuppressive and can lead to oral aversions, dietary …
Baylor Role: Lead Sponsor
Terminated
Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers
Gastric adenocarcinoma, also known as stomach cancer, is a global health problem. While surgical resection remains the only curative option for patients who develop this disease, because of its aggressive …
Recruiting
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
To prepare the CD30.CAR T cells, research staff will take some blood from the subject. This would be drawn as two separate blood collections. Alternatively, if the subject's blood counts …
Baylor Role: Lead Sponsor
Recruiting
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
To be eligible to participate in this study, patients physician must have determined that they have LCH which is not treatable by surgical intervention or observation alone. If patient chooses …
Baylor Role: Lead Sponsor